Cargando…

Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

This study is aimed at assessing the sintilimab-based regimens' safety and efficacy for advanced esophageal cancer (EC) treatment in the real world. Cases of advanced EC treated with sintilimab-based regimens in the Anyang Tumor Hospital between 1 January 2020 and 1 August 2021 were retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chenyu, Jin, Linzhi, Cheng, Xinyu, Ren, Runchuan, Zheng, Anping, Hao, Anlin, Wang, Nengchao, Zhang, Jinwen, Zhou, Fuyou, Zhang, Yaowen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410816/ https://www.ncbi.nlm.nih.gov/pubmed/36033564 http://dx.doi.org/10.1155/2022/7331687

Ejemplares similares

Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
por: Wang, Chenyu, et al.
Publicado: (2022)

Deep Learning for Automated Contouring of Gross Tumor Volumes in Esophageal Cancer
por: Jin, Linzhi, et al.
Publicado: (2022)

Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy
por: Zhang, Yaowen, et al.
Publicado: (2017)

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
por: Zeng, Xianghua, et al.
Publicado: (2023)

Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma
por: Wang, Nengchao, et al.
Publicado: (2022)

Definition and risk factors of early recurrence based on affecting prognosis of esophageal squamous cell carcinoma patients after radical resection
por: Zhang, Yaowen, et al.
Publicado: (2021)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Identification of a DNA Methylome Profile of Esophageal Squamous Cell Carcinoma and Potential Plasma Epigenetic Biomarkers for Early Diagnosis
por: Li, Xufeng, et al.
Publicado: (2014)

Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report
por: Li, Haoqian, et al.
Publicado: (2023)

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
por: Hong, Guo, et al.
Publicado: (2023)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Clinical significance of detecting circulating tumor cells in patients with esophageal squamous cell carcinoma by EpCAM-independent enrichment and immunostaining-fluorescence in situ hybridization
por: Zhang, Yaowen, et al.
Publicado: (2019)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
por: Chen, Jinzhang, et al.
Publicado: (2020)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
por: Zhao, Lei, et al.
Publicado: (2022)

Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)
por: Zhang, Zhenyang, et al.
Publicado: (2021)

A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)
por: Duan, Hongtao, et al.
Publicado: (2021)

hsa_circRNA6448-14 promotes carcinogenesis in esophageal squamous cell carcinoma
por: Zhang, Yaowen, et al.
Publicado: (2020)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Correction for: hsa_circRNA6448-14 promotes carcinogenesis in esophageal squamous cell carcinoma
por: Zhang, Yaowen, et al.
Publicado: (2020)

Alteration of plasma metabolites associated with chemoradiosensitivity in esophageal squamous cell carcinoma via untargeted metabolomics approach
por: Zhang, Yaowen, et al.
Publicado: (2020)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
por: Yang, Bo, et al.
Publicado: (2022)

Sintilimab: Aggravation of Coronavirus disease 2019: case report
Publicado: (2021)

Sintilimab-induced autoimmune diabetes: A case report and review of the literature
por: Yang, Jing, et al.
Publicado: (2022)

Case report: A rare case of sintilimab-induced gastric stenosis and literature review
por: Song, Kunkun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9cj4lo7rtoa1qcbvok8e2gg8qi